Related references
Note: Only part of the references are listed.Is CHEK2 a cause of the Li-Fraumeni syndrome?
D. G. Evans et al.
JOURNAL OF MEDICAL GENETICS (2008)
Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues
Kay E. Gurley et al.
MOLECULAR CANCER RESEARCH (2007)
HAda3 regulates p14ARF-induced p53 acetylation and senescence
P. Sekaric et al.
ONCOGENE (2007)
Breast cancer prognostication and prediction in the postgenomic era
P. E. Lonning et al.
ANNALS OF ONCOLOGY (2007)
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen
Philippe Bertheau et al.
PLOS MEDICINE (2007)
Increased risk of breast cancer associated with CHEK2*1100delC
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Therese Sorlie et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Vidar Staalesen et al.
CLINICAL CANCER RESEARCH (2006)
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
M. A. Christophorou et al.
NATURE (2006)
Policing of oncogene activity by p53
Alejo Efeyan et al.
NATURE (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
O Thuerigen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Regulation of the p53 transcriptional activity
G Liu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress
D Speidel et al.
ONCOGENE (2006)
Transcription-independent pro-apoptotic functions of p53
UM Moll et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage
C Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer
J Hannemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
p53 must be competent for transcriptional regulation to suppress tumor formation
M Nistér et al.
ONCOGENE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
p53-RI75H mutant gains new function in regulation of doxorubicin-induced apoptosis
WP Tsang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Genomics in breast cancer - therapeutic implications
PE Lonning et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance
PE Lonning
TRENDS IN MOLECULAR MEDICINE (2004)
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis
JE Chipuk et al.
SCIENCE (2004)
P14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts
S Khan et al.
ONCOGENE (2004)
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer:: A Spanish breast cancer research group (GEICAM-9903) phase III study
E Alba et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
V Staalesen et al.
ONCOGENE (2004)
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks
G Buscemi et al.
ONCOGENE (2004)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
p53's believe it or not: Lessons on transcription-independent death
JE Chipuk et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2003)
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells
PV Jallepalli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Chk2 activates E2F-1 in response to DNA damage
C Stevens et al.
NATURE CELL BIOLOGY (2003)
Germline TP53 mutations and Li-Fraumeni syndrome
JM Varley
HUMAN MUTATION (2003)
Chemotherapy response and resistance
S Lee et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner
A Hirao et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila
M Peters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
Analysis of CHK2 in vulval neoplasia
A Reddy et al.
BRITISH JOURNAL OF CANCER (2002)
Concomitant inactivation of p53 and Chk2 in breast cancer
A Sullivan et al.
ONCOGENE (2002)
Chk2 kinase - A busy messenger
J Bartek et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway
J Falck et al.
ONCOGENE (2001)
Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA
RI Skotheim et al.
CANCER GENETICS AND CYTOGENETICS (2001)
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
J Falck et al.
NATURE (2001)
ATM and ATR: networking cellular responses to DNA damage
Y Shiloh
CURRENT OPINION IN GENETICS & DEVELOPMENT (2001)
Characterization of turner-associated Chk2 mutations
XL Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
DNA damage-induced activation of p53 by the checkpoint kinase Chk2
A Hirao et al.
SCIENCE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
